Activist Investor Ramius Capital Wins Two Board Seats

January 6th, 2011
| More
SurModics, a drug delivery pharmaceutical company, announced that it has resolved a dispute with Ramius Capital Group by agreeing to grant two board seats to Ramius. Ramius Capital, a New York-based activist investor, demanded three board seats in response to the company’s "failed growth investments, failed acquisitions and excessive spending.” Jeffrey Smith, Chief Investment Officer of Ramius, and Dr. David Dantzker of Wheatley Partners joined the SurModics board Tuesday in place of John Meslow and Kenneth Keller. In response to the appointments, Jeffrey Smith said, “We are pleased to have worked constructively with SurModics to reach this settlement. Dr. Dantzker and I look forward to working diligently and constructively with our fellow Board members to enhance value for all SurModics shareholders and we are confident that our collective experience will prove valuable to the Company.“

Ramius currently holds a 12% stake in SurModics.
See Source
For Detailed Investor Profiles on these Investors, click below:
Ramius Capital Group
Related People: Jeffrey Smith; Jeffrey Solomon; Mark R. Mitchell; Morgan Stark; Peter Cohen; Thomas Strauss
Related Entities: Cowen Group Inc. (NASDAQ: COWN); Ramius Alternative Investments; Ramius Credit Fund; Ramius Enterprise LP; Ramius Intermediate Fund; Ramius Multi-Strategy Fund; Ramius Value and Opportunity Fund
Related Article Tags: Shareholder Activists, Corporate Raiders and Proxy Battles

More Recent Headlines

Polar Capital’s Discovery Fund to Close

A Strong December Leads to Double Digit Gains for Paulson’s Funds

Galleon Co-Founder Starting Firm

FrontPoint Announces New $1 Billion Fund

Quantedge Capital Looks to Double Assets Under Management

David Einhorn Announces Favorite Long Position for 2011

Alleged Hedge Fund Tipster Remains Jailed

The Big Hedge Fund Killing in For Profit Education

Greenlight Capital’s David Einhorn fears another crisis

Teall Edds and Stuart Wilson’s Orchard Capital Partners outperforms